TriSalus Life Sciences initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of TriSalus Life Sciences with an Outperform rating and $10 price target. The analyst views TriSalus as a “hybrid MedTech play” with the potential to improve the therapeutic profile of existing agents in hard-to-treat cancers. The company’s pressure-enabled drug delivery technology utilizes a proprietary smartvalve catheter to overcome physiologic challenges within tumor vasculature and has been shown to improve outcomes in complex patients, the analyst tells investors in a research note. The firm likes TriSalus’ current commercial opportunity in liver cancer with TriNav.